Uterine Cancer Market Size, Share & Trends Analysis Report By Type (Endometrial Adenocarcinoma, Adenosquamous Carcinoma, Papillary Serous Carcinoma, Uterine Sarcoma), By Treatment (Diagnosis, Therapeutic Treatment, Surgery), By End-Users (Hospitals, Diagnostic Centers, Drug Stores, Online Pharmacies, Other End Users) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Market Overview

The global uterine cancer market share is expected to grow at a CAGR of 4.92% during the forecast period (2024-32). The continuous analysis and development focused on diagnosing and treating uterine cancer is anticipated to drive market growth over the forecast period.

Highlights

• Endometrial adenocarcinoma dominates the type segment.
• Surgery dominates the treatment segment.
• Hospital dominates the end-user segment.
• North America is the highest shareholder in the global market.

Market Overview

Endometrial cancer, another name for uterine cancer, begins in the endometrium, the lining that lines the uterus. This is a highly prevalent gynecological cancer, with symptoms such as irregular vaginal bleeding, pelvic pain, or pain during sexual activity. Uterine cancer is more likely to be diagnosed and cause suffering for women between the ages of 42 and 50 who are going through menopause or post-menopause.

The precise etiology of uterine cancer remains uncertain; however, due to its prevalent symptoms, such as intermittent bleeding, early detection is feasible. Papillary serous carcinoma is the most aggressive and hazardous among the four types of uterine cancer due to its tendency to recur even after early diagnosis and treatment. Uterine sarcoma begins in the myometrium and uterine muscle wall and extends throughout the entire uterus before potentially traveling through the bloodstream to the lungs.

Market Dynamics

Global Uterine Cancer Market Drivers

Increasing Prevalence of Uterine Cancer

The global increase in uterine cancer cases is one factor driving the market's expansion. The aging population, alterations in lifestyle, and environmental factors are some of the possible causes of the rising incidence of uterine cancer. According to World Cancer Research Fund International, endometrial cancer, also known as womb or corpus uteri cancer, is the sixth most common cancer in women and the fifteenth most common cancer globally. In a similar vein, 417,000 new diagnoses were made worldwide in 2020, with cases doubling in women under 40. The mortality rate associated with uterine cancer experienced an average annual increase of 1.9% from 1971 to 2014. Moreover, in the USA, it is anticipated to rank sixth in terms of female mortality and fourth in terms of new cancer cases by 2023.

Awareness and Early Detection Campaigns

Increasing public knowledge of uterine cancer risk factors, symptoms, and the importance of regular screenings can help prevent early detection. Campaigns to raise awareness and public health initiatives help increase the number of women seeking medical attention for symptoms, positively affecting market growth. The International Gynecologic Cancer Society, supported by patient advocacy groups worldwide, is calling for a worldwide initiative to raise awareness about uterine and endometrial cancer. Starting in 2023, June will be officially designated as Uterine Cancer Awareness Month.

In the United States, uterine cancer ranks fourth among cancer diagnoses for women. The National Comprehensive Cancer Control Program (NCCCP) of the Centers for Disease Control and Prevention partnered with the Inside Knowledge: Get The Facts About Gynecologic Cancer campaign to offer women and healthcare providers facilitated discussions about uterine cancer to increase awareness of the disease. Local NCCCP grantees created and led customized, community-based facilitated discussions for providers and participants following standardized training. Such factors create opportunities for market growth.

Global Uterine Cancer Market Restraints

High Treatment Costs

Treatments for uterine cancer, such as radiation therapy, chemotherapy, and surgery, can be very expensive. Access to care may be hampered by high treatment costs, especially in areas with inadequate healthcare resources. Radiation therapy typically costs between INR 1,50,000 and INR 4,50,000 (USD 2,000 to USD 6,100) for the duration of treatment, while surgical interventions typically cost between INR 2,00,000 and INR 5,00,000 (USD 2,700 to USD 6,800). Such high costs hinder market growth.

Moreover, the price of treating uterine cancer can vary depending on several factors. Patients and their families can anticipate and prepare for the related costs by being aware of these factors. The course of treatment and related expenses are largely dependent on the stage and type of uterine cancer. Compared to advanced-stage cancers, which may require more extensive therapies, early-stage cancers may require less aggressive treatment, which could result in lower overall expenses.

Global Uterine Cancer Market Opportunities

Advancements in Targeted Therapies

The development of targeted treatments, such as immunotherapies and precision medicine methods, offers a chance to maximize therapeutic efficacy while reducing adverse effects. Treatment options for uterine cancer have changed significantly as a result of developments in genomic profiling and biomarker identification. These advancements have made it possible to detect uterine cancer at an earlier stage and have enhanced the understanding of genetic and molecular traits of the disease's subtypes. As this field of research continues to develop, it has the potential to further improve patient outcomes and increase the range of therapeutic options available to individuals with uterine cancer.

Regional Analysis

Based on region, the global uterine cancer market is segmented into North America, Asia-Pacific, Europe, Latin America, and the Middle East and Africa.

North America Dominates the Global Market

North America is the most significant global uterine cancer market shareholder and is expected to expand substantially over the forecast period. This is because of factors like the country's advanced healthcare system and the growing public understanding of cancer diagnosis. According to the American Cancer Society, there will likely be 65,950 new cases of uterine body or corpus cancer diagnosed in the US this year. Typically, endometrial cancer strikes women who have gone through menopause. Endometrial cancer typically affects women around the age of 60.

Additionally, a large number of clinical studies on endometrial cancer are carried out in the area under investigation. For example, the Canada-based Sunnybrook Health Sciences Centre funded a clinical trial in July 2022 to evaluate the impact of megestrol acetate on patients with grade 2 endometrioid endometrial cancer who were awaiting decisive surgery. Moreover, several industry participants are executing strategic plans throughout the area. In February of 2022, Karyopharm Therapeutics Inc., a US-based company, announced encouraging top-line findings from the Phase 3 Selinexor endometrial cancer study. This study assessed the safety and effectiveness of front-line maintenance therapy with selinexor in patients with advanced or recurrent disease.

In Europe, the presence of critical market players suggests that the region will have a significant share. The market growth is anticipated to be enhanced during the forecast period due to continuous research and development efforts focused on early detection of uterine cancer. Recent research conducted by the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust in the United Kingdom has demonstrated the efficacy of the novel cancer drug Tisotumab Vedotin (TV) in drug-resistant cancer patients. Notably, 7% of the endometrial cancer tumors exhibited cessation of growth and subsequent shrinkage.

Furthermore, European cancer centers and hospitals provide a variety of treatments for uterine cancer, such as hormonal therapy, radiation therapy, chemotherapy, and surgery (hysterectomy). There is a widespread emphasis on interdisciplinary care. For instance, the Royal Marsden provides a specialized service in gynecological cancer care, including staging, treatment, and support, at its two locations in London and Surrey: Chelsea and Sutton. The term "gynecological cancers" encompasses a wide range of malignancies that can affect the female reproductive system. Such factors propel regional market growth.

Segmental Analysis

The global uterine cancer market is segmented into type, treatment, and end-user.

Based on type, the global uterine cancer market is segmented into endometrial adenocarcinoma, adenosquamous carcinoma, papillary serous carcinoma, and uterine sarcoma.

The endometrial adenocarcinoma segment dominates the global market. A particular kind of cancer known as endometrial adenocarcinoma develops in the cells that line the endometrium, or inner lining of the uterus. This type of uterine cancer is the most prevalent. Endometrial adenocarcinoma arises when the cells in the endometrium undergo a glandular transformation, leading to the development of cancerous adenocarcinomas. The grading of endometrial cancer is established by assessing the degree of resemblance between the cancer cells and the glands found in a typical, healthy endometrium. More cancer cells undergo glandular development in lower-grade cancers (grades 1 and 2). On the other hand, higher-grade cancers (grade 3) exhibit greater disorganization in cancer cells, resulting in the absence of gland formation.

Based on treatment, the global uterine cancer market is segmented into diagnosis (pelvic examination, endometrial biopsy, transvaginal ultrasound, computed tomography (CT or CAT) scan, magnetic resonance imaging (MRI)), therapeutic treatment (radiation therapy, chemotherapy, hormone therapy), and surgery (hysterectomy and lymphadenectomy).

The surgery segment owns the highest market share. Surgery involves the excision of a tumor, along with a contiguous area of healthy tissue. Typically, it is the primary method of treatment for uterine cancer. A surgical gynecologic oncologist is a medical specialist who focuses on the use of surgical procedures to treat gynecologic cancer. A hysterectomy is among the common procedures. A simple hysterectomy, which involves removing the uterus and cervix, or a radical hysterectomy, which involves removing the uterus, cervix, upper part of the vagina, and surrounding tissues, will be performed by the surgeon based on the severity of the cancer. The surgeon will usually perform a bilateral salpingo-oophorectomy (removal of both ovaries and fallopian tubes) for patients who have experienced menopause.

Based on the end-user, the global uterine cancer market is segmented into hospitals, diagnostic centers, drug stores, online pharmacies, and other end-users.

The hospital segment dominates the global market. Hospitals are essential for the provision of uterine cancer diagnostic services. This covers biopsies, such as dilation and curettage (D&C) and endometrial biopsy, as well as imaging tests like transvaginal ultrasound and magnetic resonance imaging (MRI). Surgery related to uterine cancer, such as hysterectomy (removal of the uterus) and lymph node dissection, is frequently performed in hospitals. Hospitals might also provide additional treatment options like chemotherapy and radiation therapy.

Recent Developments

• December 2023 – Researchers at QUT found a promising new treatment for a deadly form of endometrial cancer, which affects 15-20% of patients and has a poor prognosis if the cancer spreads or returns after initial treatment. An intriguing discovery, according to Dr. Asmerom, was that endometrial cancer patient xenografts with activated FGFR2c showed a notable decrease in tumor blood vessel formation and immune cells (M2-macrophages), which inhibit the immune system from eliminating cancer cells after receiving FGFR inhibitor treatment for seven days.
• October 2023- Merck and Co., Inc. presented findings from the Phase 3 KEYNOTE-A39 trial (also known as EV-302), which was conducted in conjunction with Seagen and Astellas. The trial compared chemotherapy (gemcitabine plus cisplatin or carboplatin) with KEYTRUDA, Merck's anti-PD-1 therapy, plus Padcev (enfortumab vedotin-ejfv), an antibody-drug conjugate, in patients with previously untreated domestically superior or metastatic urothelial carcinoma.